Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Dickkopf-3 links HSF1 and YAP/TAZ signalling to control aggressive behaviours in cancer-associated fibroblasts

  • Ferrari, Nicola
  • Ranftl, Romana
  • Chicherova, Ievgeniia
  • Slaven, Neil D.
  • Moeendarbary, Emad
  • Farrugia, Aaron J.
  • Lam, Maxine
  • Semiannikova, Maria
  • Westergaard, Marie C. W.
  • Tchou, Julia
  • Magnai, Luca
  • Calvo, Fernando
© The Author(s) 2019., Aggressive behaviours of solid tumours are highly influenced by the tumour microenvironment. Multiple signalling pathways can affect the normal function of stromal fibroblasts in tumours, but how these events are coordinated to generate tumour-promoting cancer-associated fibroblasts (CAFs) is not well understood. Here we show that stromal expression of Dickkopf-3 (DKK3) is associated with aggressive breast, colorectal and ovarian cancers. We demonstrate that DKK3 is a HSF1 effector that modulates the pro-tumorigenic behaviour of CAFs in vitro and in vivo. DKK3 orchestrates a concomitant activation of β-catenin and YAP/TAZ. Whereas β-catenin is dispensable for CAF-mediated ECM remodelling, cancer cell growth and invasion, DKK3-driven YAP/TAZ activation is required to induce tumour-promoting phenotypes. Mechanistically, DKK3 in CAFs acts via canonical Wnt signalling by interfering with the negative regulator Kremen and increasing cell-surface levels of LRP6. This work reveals an unpredicted link between HSF1, Wnt signalling and YAP/TAZ relevant for the generation of tumour-promoting CAFs., This work was funded by Worldwide Cancer Research (Grant 15–0273) and the Institute of Cancer Research. F.C. is also funded by Cancer Research UK (C57744/A22057) and the Ramon y Cajal Research Program (MINECO, RYC-2016–20352). Spanish funding to F.C. is partially supported by the European Regional Development Fund.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

SREBP1 drives Keratin-80-dependent cytoskeletal changes and invasive behavior in endocrine-resistant ERα breast cancer

  • Perone, Ylenia
  • Farrugia, Aaron J.
  • Rodríguez-Meira, Alba
  • Győrffy, Balázs
  • Ion, Charlotte
  • Uggetti, Andrea
  • Chronopoulos, Antonios
  • Marrazzo, Pasquale
  • Faronato, Monica
  • Shousha, Sami
  • Davies, Claire
  • Steel, Jennifer H.
  • Patel, Naina
  • Rio Hernandez, Armando del
  • Coombes, Charles
  • Pruneri, G.
  • Lim, Adrian
  • Calvo, Fernando
  • Magnani, Luca
© The Author(s) 2019., Approximately 30% of ERα breast cancer patients relapse with metastatic disease following adjuvant endocrine therapies. The connection between acquisition of drug resistance and invasive potential is poorly understood. In this study, we demonstrate that the type II keratin topological associating domain undergoes epigenetic reprogramming in aromatase inhibitors (AI)-resistant cells, leading to Keratin-80 (KRT80) upregulation. KRT80 expression is driven by de novo enhancer activation by sterol regulatory element-binding protein 1 (SREBP1). KRT80 upregulation directly promotes cytoskeletal rearrangements at the leading edge, increased focal adhesion and cellular stiffening, collectively promoting cancer cell invasion. Shearwave elasticity imaging performed on prospectively recruited patients confirms KRT80 levels correlate with stiffer tumors. Immunohistochemistry showed increased KRT80-positive cells at relapse and, using several clinical endpoints, KRT80 expression associates with poor survival. Collectively, our data uncover an unpredicted and potentially targetable direct link between epigenetic and cytoskeletal reprogramming promoting cell invasion in response to chronic AI treatment., L.M. was supported by a CRUK fellowship (C46704/A23110). Y.P. was supported by a CRUK Studentship (PS2099). A.J.F. and F.C. are funded by the Institute of Cancer Research, London (UK). F.C. is also funded by Worldwide Cancer Research (Grant 15-0273), Cancer Research UK (C57744/A22057) and the Ramon y Cajal Research Program (MINECO, RYC-2016-20352).